ADMA Biologics, Inc. (ADMA)
ADMA Stock Price Chart
Explore ADMA Biologics, Inc. interactive price chart. Choose custom timeframes to analyze ADMA price movements and trends.
ADMA Company Profile
Discover essential business fundamentals and corporate details for ADMA Biologics, Inc. (ADMA) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
17 Oct 2013
Employees
685.00
Website
https://www.admabiologics.comCEO
Adam S. Grossman
Description
ADMA Biologics, Inc. functions as a biopharmaceutical company specializing in the development, manufacturing, and commercialization of advanced biologic therapies derived from blood plasma. These specialized products are engineered to address immune system disorders and infectious diseases, catering to markets across the United States and internationally. Their current product portfolio includes BIVIGAM and ASCENIV, both intravenous immune globulin (IVIG) treatments prescribed for primary humoral immunodeficiency (PI). Additionally, the company offers Nabi-HB, utilized for immediate treatment following acute exposure to the Hepatitis B virus and other specified exposures. Beyond its existing offerings, ADMA is actively developing a pipeline of new plasma-derived therapeutics. This includes immunoglobulin products specifically targeting the prevention and treatment of S. pneumonia infections. The company also oversees its own facilities for source plasma collection. Product distribution is managed through a comprehensive network involving independent distributors, sales agents, specialty pharmacies, and other alternative healthcare providers. ADMA Biologics, Inc. was founded in 2004 and maintains its corporate headquarters in Ramsey, New Jersey.
ADMA Financial Timeline
Browse a chronological timeline of ADMA Biologics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 5 Aug 2026
EPS estimate is $0.16, while revenue estimate is $125.34m.
Earnings released on 6 May 2026
EPS came in at $0.19 falling short of the estimated $0.19 by -1.71%, while revenue for the quarter reached $114.49m , missing expectations by -18.20%.
Earnings released on 25 Feb 2026
EPS came in at $0.20 surpassing the estimated $0.19 by +8.11%, while revenue for the quarter reached $139.16m , missing expectations by -0.31%.
Earnings released on 5 Nov 2025
EPS came in at $0.16 matching the estimated $0.16, while revenue for the quarter reached $134.22m , missing expectations by -3.99%.
Earnings released on 6 Aug 2025
EPS came in at $0.15 surpassing the estimated $0.14 by +7.14%, while revenue for the quarter reached $121.98m , missing expectations by -6.38%.
Earnings released on 7 May 2025
EPS came in at $0.14 falling short of the estimated $0.16 by -12.50%, while revenue for the quarter reached $114.80m , missing expectations by -5.75%.
Earnings released on 3 Mar 2025
EPS came in at $0.14 falling short of the estimated $0.15 by -6.67%, while revenue for the quarter reached $117.55m , beating expectations by +8.19%.
Earnings released on 7 Nov 2024
EPS came in at $0.15 surpassing the estimated $0.13 by +15.38%, while revenue for the quarter reached $119.84m , beating expectations by +5.68%.
Earnings released on 8 Aug 2024
EPS came in at $0.13 surpassing the estimated $0.08 by +62.50%, while revenue for the quarter reached $107.19m , beating expectations by +24.05%.
Earnings released on 9 May 2024
EPS came in at $0.08 surpassing the estimated $0.06 by +33.33%, while revenue for the quarter reached $81.88m , beating expectations by +5.96%.
Earnings released on 28 Feb 2024
EPS came in at $0.04 surpassing the estimated -$0.01 by +420.00%, while revenue for the quarter reached $73.90m , beating expectations by +2.43%.
Earnings released on 8 Nov 2023
EPS came in at $0.01 surpassing the estimated $0.00 by +233.33%, while revenue for the quarter reached $67.27m , missing expectations by -1.77%.
Earnings released on 9 Aug 2023
EPS came in at -$0.02 falling short of the estimated -$0.02 by -19.98%, while revenue for the quarter reached $60.12m , beating expectations by +8.33%.
Earnings released on 10 May 2023
EPS came in at -$0.03 surpassing the estimated -$0.05 by +40.00%, while revenue for the quarter reached $56.91m , beating expectations by +6.56%.
Earnings released on 23 Mar 2023
EPS came in at -$0.06 surpassing the estimated -$0.07 by +14.29%, while revenue for the quarter reached $49.98m , beating expectations by +8.82%.
Earnings released on 9 Nov 2022
EPS came in at -$0.08 matching the estimated -$0.08, while revenue for the quarter reached $41.09m , beating expectations by +19.16%.
Earnings released on 10 Aug 2022
EPS came in at -$0.07 surpassing the estimated -$0.09 by +22.22%, while revenue for the quarter reached $33.91m , beating expectations by +6.58%.
Earnings released on 11 May 2022
EPS came in at -$0.10 falling short of the estimated -$0.08 by -25.00%, while revenue for the quarter reached $29.10m , beating expectations by +12.37%.
Earnings released on 24 Mar 2022
EPS came in at -$0.09 surpassing the estimated -$0.10 by +10.00%, while revenue for the quarter reached $26.38m , beating expectations by +21.26%.
Earnings released on 10 Nov 2021
EPS came in at -$0.13 surpassing the estimated -$0.15 by +13.33%, while revenue for the quarter reached $20.68m , missing expectations by -11.76%.
Earnings released on 11 Aug 2021
EPS came in at -$0.15 matching the estimated -$0.15, while revenue for the quarter reached $17.83m , missing expectations by 0.00%.
ADMA Stock Performance
Access detailed ADMA performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
